Strides Pharma gets USFDA nod for generic medication
Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.
Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.
Singapore-based Strides Pharma Global Pte Ltd has received approval for Levetiracetam Oral Solution USP, 100 mg/mL, from the US Food & Drug Administration (USFDA), the company said in a regulatory filing.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Keppra Oral Solution of UCB, Inc, it added.
It is used in the treatment of seizures.
As per IQVIA data, the Levetiracetam Oral Solution has a market size of USD 55 million.
The product will be manufactured at the company's facility in Bengaluru, the drug firm said.
The company said it now has 260 cumulative abbreviated new drug application (ANDA) filings with the USFDA, of which over 230 filings have been approved.
The company said it has set a target to launch 60 new products over three years in the US.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
12:22 PM IST